Dr. Nisha A. Mohindra
Claim this profileNorthwestern University
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
10 reported clinical trials
19 drugs studied
Area of expertise
1Lung Cancer
Stage III
Stage IV
Stage II
2Non-Small Cell Lung Cancer
Stage III
Stage IV
Stage II
Affiliated Hospitals
Clinical Trials Nisha A. Mohindra is currently running
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Genetic Testing
for Early-Stage Lung Cancer
This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.
Recruiting0 awards N/A4 criteria
More about Nisha A. Mohindra
Clinical Trial Related4 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Nisha A. Mohindra has experience with
- Carboplatin
- Pembrolizumab
- Cisplatin
- Atezolizumab
- Paclitaxel
- Pemetrexed
Breakdown of trials Nisha A. Mohindra has run
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Relapse
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Nisha A. Mohindra specialize in?
Nisha A. Mohindra focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage III patients, or patients who are Stage IV.
Is Nisha A. Mohindra currently recruiting for clinical trials?
Yes, Nisha A. Mohindra is currently recruiting for 4 clinical trials in Chicago Illinois. If you're interested in participating, you should apply.
Are there any treatments that Nisha A. Mohindra has studied deeply?
Yes, Nisha A. Mohindra has studied treatments such as Carboplatin, Pembrolizumab, Cisplatin.
What is the best way to schedule an appointment with Nisha A. Mohindra?
Apply for one of the trials that Nisha A. Mohindra is conducting.
What is the office address of Nisha A. Mohindra?
The office of Nisha A. Mohindra is located at: Northwestern University, Chicago, Illinois 60611 United States. This is the address for their practice at the Northwestern University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.